Member Info for Uncanny

scrapping the sub shares which with the third tranche halved the SP! Should have read 1st tranche of the three

Sorry Drac didn’t answer this bit, but IMHO..... Are the BoD going to change their funding tune? Maybe!? Use ABO for CLN’s / warrants but with a longer conversion time frame and let VAL be in the driving seat like Oncology Ventures announced in March 2019 scrapping the sub shares which with the third tranche halved the SP! Give shareholders the opportunity to absorb the dilution through a 2 for 10 placing - much better !!!! They have to now the SP is at 0.315p IMHO! There has always been unrest and disappointment at each placing as it has always been a short to medium term (3 months) “oh poo, we’re running out of money” type scenario, but now we have fighting opposites on the spectrum of IP completion and desperation to get the IP across the finish line when they are so close to getting to P3 on two IP’s: 1. IP which is on the cusp of being commercialised or maybe has been but we don’t know it yet for 201 and 401. 201 going from P1/2 straight to P3 perhaps. What was the results of 201 P1/2? 2. Need funding at a time when the SP is on its knees and the BoD realise shareholders have had enough and will need to vote this through - we need positive news and quick this month. Surely they know this and shareholders won’t just “roll over and tickle me tummy”! 3. We know 101 / FIT is financed but maybe for no upfront fee(?) VAL do the science and ABO fund it, going 50:50? 4. 301 to end PC and start P1 Lots of unknowns and fingers crossed for those that are on higher averages like me, buying in on the hype Dec 2017 and averaged down umpteen times. GLA and AIMHO.

Was it a good penny Valju?

Sorry..... some big positives in the IP that may fail to see

Of course not Dracula! I have 2.5 times the number of shares the BoD have combined and despite the negativity of the dilution, there are in fact

It was published Oct 2018 but the DCF fundamentals remain the same as do the peer valuations and market penetration potential IMHO albeit with the caveat being the dilution. At present the 10.28p equates now to 7.24p and the further progress of 201 derisked in to a P3 if we can jump from P1/2 to commercialise is more like 15.27p. Obviously this needs to be discounted again once we get confirmation of ABO and any placing but provides a rough guide IMHO.

“As discussed, our total probability of success weighted NPV for VAL201 and VAL401 is £54.64 million, more than six times the current market cap. We use this to set our initial target price of 10.28p per share. As ValiRx moves along the valuation curve we expect to reduce our discount rate and increase the probability of success rate, thereby providing further upside potential. We point out that, assuming successful approval for both drugs, the unrisked NPV (100% probability of success) rises to £115.16 million, suggesting c.13 times upside. Accordingly, we initiate coverage of ValiRx with a stance of Conviction Buy.” There were 531 million shares in issue when published and currently 752 million now,

Don’t understand Drac?

Well Drac, mmmm nothing wrong, its just timing so maybe they are / or in the midst of something for 201 and we know with 401 that 2 LoI in place, hopefully more to follow and details. P1/2 just finished for 201 so early days but we are led to believe that interested pharma's have been keeping their ears and eyes to the ground on progress. We still await 201 news which we believe ended EO May so we are only 1 week on. 401 we await a progress update. In a nutshell, as soon as VAL have got something to say l am sure they will do - well they have to from a regulatory perspective. We will have to wait and see.

Here was an example of a deal, similar to 201, which completed P1/2 and straight to P3: ArQule Inc. (NASDAQ: ARQL) Pharmaceutica Ltd. (SIX: BSLN) for oncology drug candidate ARQ 087 (derazantinib), which targets announced a license agreement with Basilea the fibroblast growth factor receptor (FGFR) family of kinases. The exclusive license is worldwide, excluding the People's Republic of China, Hong Kong, Macau and Taiwan. The drug has demonstrated favorable clinical data in a biomarker-driven Phase 1/2 study in bile duct cancer patients and is recruiting for a Phase III trial. Under the deal ArQule received an upfront payment of $10 million and is eligible for up to $326 million in regulatory and commercial milestones. ArQule is also entitled to receive staggered single-digit to double-digit royalties on net sales upon commercialisation. Basilea will be responsible for all costs and expenses of development, manufacture and commercialization in its territory. Under certain circumstances, ArQule may have the opportunity to promote derazantinib in the US directly.

They have to announce exceptional news-flow now before the AGM to get investors attention and spike the SP.

Duplex, welcome with your second post on LSE

Just wondered if anyone emailed the company to confirm whether the FIT Bio HIV P2 drug is being progressed? TIA

Very big market - l wonder where the FIT product fits in, if you pardon the pun! The FIT purchase was a great deal IMHO.

I would expect so seeing that its in P2 and we like to commercialise at P2. Does anyone know what sort of success it has had to date, plus comparative drugs and value?

Indeed Marmited. I am looking for a torrent of updates from VAL. 1. 201 dose escalation 4-16mg and better than 30% plus meta growth interim analysis 2. 401 LoI’s / Contracts / Funding for SEEK 3. 101 & FIT details 4. 301 ending PCT and if further reduction in Legions from 50% 5. More details on ABO revised deal with hopefully relaxing of previous terms 6. Further IP patents The share price is holding steady so it looks like the market are also sitting patiently to await new developments which l hope are both positive and share price enhancing.

Morning mate and loved the post LOL.

Well you lot are out in ambush mode today, LOL.

Not taking sides but we’ve had RNs’s every few months l think and they have to before each 2 months on an RNS?

What news?